Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$48.56
+0.3%
$51.31
$35.38
$78.48
$4.67B1.741.81 million shs1.78 million shs
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$77.15
+0.0%
$76.39
$59.68
$153.86
$69.46B2.2928.35 million shs20.15 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$48.11
-1.9%
$51.45
$22.28
$59.55
$19.46B1.058.04 million shs5.00 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.93
-1.4%
$8.96
$6.13
$11.97
$1.49B2.375.35 million shs4.82 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%-11.71%-16.52%-8.78%+24.86%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
0.00%+0.14%-15.00%+1.54%+24.90%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-9.77%-8.71%+16.13%+97.26%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-10.39%+2.49%+4.14%+34.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$48.56
+0.3%
$51.31
$35.38
$78.48
$4.67B1.741.81 million shs1.78 million shs
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$77.15
+0.0%
$76.39
$59.68
$153.86
$69.46B2.2928.35 million shs20.15 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$48.11
-1.9%
$51.45
$22.28
$59.55
$19.46B1.058.04 million shs5.00 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.93
-1.4%
$8.96
$6.13
$11.97
$1.49B2.375.35 million shs4.82 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%-11.71%-16.52%-8.78%+24.86%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
0.00%+0.14%-15.00%+1.54%+24.90%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-9.77%-8.71%+16.13%+97.26%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-10.39%+2.49%+4.14%+34.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.53
Moderate Buy$65.4734.82% Upside
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
2.64
Moderate Buy$107.8839.83% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-25.73% Downside
Novavax, Inc. stock logo
NVAX
Novavax
2.10
Hold$12.1335.78% Upside

Current Analyst Ratings Breakdown

Latest MRNA, CRSP, HOOD, and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetMarket Perform$50.00 ➝ $56.00
5/11/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingOutperform$76.00
5/7/2026
Novavax, Inc. stock logo
NVAX
Novavax
DowngradeHold (C-)Sell (D)
5/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetBuy$80.00 ➝ $82.00
5/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Boost Price TargetHold$8.00 ➝ $9.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
4/30/2026
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
Lower Price TargetBuy$102.00 ➝ $90.00
4/29/2026
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
Reiterated RatingMarket Outperform$155.00
(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,334.36N/AN/A$20.17 per share2.41
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$4.47B15.53$2.18 per share35.31$10.15 per share7.60
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B9.82N/AN/A$22.14 per share2.17
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.31$3.46 per share2.58($0.79) per share-11.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$1.88B$2.0737.2731.492.5241.12%21.39%4.73%7/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)

Latest MRNA, CRSP, HOOD, and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million
5/4/2026Q1 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/28/2026Q1 2026
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$0.3853$0.38-$0.0053$0.38$1.14 billion$1.07 billion
3/31/2026Q1 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$1.28N/A-$1.28N/A$1.46 million
2/26/2026Q4 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.66$0.11+$0.77$0.11$90.26 million$136.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.32
17.97
17.96
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
N/A
1.22
1.22
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.48
2.45

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
93.27%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
19.95%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.45 million92.50 millionOptionable
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
2,900900.51 million720.85 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.44 million162.79 millionOptionable

Recent News About These Companies

3 Small-Cap Stocks That Fall Short
Why Novavax (NVAX) Stock Is Trading Up Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$48.56 +0.15 (+0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$48.80 +0.23 (+0.48%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Robinhood Markets stock logo

Robinhood Markets NASDAQ:HOOD

$77.15 +0.01 (+0.01%)
Closing price 04:00 PM Eastern
Extended Trading
$77.08 -0.07 (-0.08%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Robinhood Markets, Inc. operates financial services platform in the United States. Its platform allows users to invest in stocks, exchange-traded funds (ETFs), American depository receipts, options, gold, and cryptocurrencies. The company offers fractional trading, recurring investments, fully-paid securities lending, access to investing on margin, cash sweep, instant withdrawals, retirement program, around-the-clock trading, and initial public offerings participation services. It also provides various learning and education solutions comprise Snacks, an accessible digest of business news stories for a new generation of investors.; Learn, which is an online collection of beginners' guides, feature tutorials, and financial dictionary; Newsfeeds that offer access to free, premium news from sites from various sites, such as Barron's, Reuters, and Dow Jones. In addition, the company offers In-App Education, a resource that covers investing fundamentals, including why people invest, a stock market overview, and tips on how to define investing goals, as well as allows customers to understand the basics of investing before their first trade; and Crypto Learn and Earn, an educational module available to various crypto customers through Robinhood Learn to teach customers the basics related to cryptocurrency. Further, it provides Robinhood credit cards, cash card and spending accounts, and wallets. Robinhood Markets, Inc. was incorporated in 2013 and is headquartered in Menlo Park, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$48.11 -0.93 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$48.14 +0.03 (+0.06%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.93 -0.13 (-1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$8.98 +0.04 (+0.50%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.